Today, a Director at Fate Therapeutics (FATE), Amir Nashat, sold shares of FATE for $1.38M.
Following Amir Nashat’s last FATE Sell transaction on October 04, 2013, the stock climbed by 9.6%.
See today’s analyst top recommended stocks >>
Currently, Fate Therapeutics has an average volume of 648.9K.
Based on 4 analyst ratings, the analyst consensus is Strong Buy with an average price target of $17.33, reflecting a 8.0% upside.
Amir Nashat’s trades have generated a -140.4% average return based on past transactions. DailyInsider proprietary algorithm detects trades by the most influential insiders and selects attractive trading opportunities daily. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Fate Therapeutics, Inc. is a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorder. It programmed cellular therapeutics for the treatment of life threatening diseases, hematologic malignancies, genetic disorders and diseases resulting from the dysregulation of the immune system.
